GlassScriptPhysician profile
Christopher L Thompson
NPI 1942544119
$77,733.51
in general payments reported to CMS, 2019-2025
34 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,494 · 2022: $4,759 · 2023: $14K · 2024: $20K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $18K · Travel and Lodging: $10K · Consulting Fee: $6,875 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,992.00 |
| Food and Beverage | $17,856.10 |
| Travel and Lodging | $10,395.36 |
| Consulting Fee | $6,875.00 |
| Education | $361.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,406.25 | 2021-2025 | |
| Ucb, INC. | $23,272.61 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $4,612.97 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $4,479.18 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $3,307.15 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,989.41 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $1,848.90 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $1,786.45 | 2022-2024 | Vtama |
| Amgen INC. | $1,582.84 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,573.58 | 2021-2025 | |
| Leo Pharma INC. | $1,407.84 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $1,089.96 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $982.94 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $784.14 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $500.24 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $437.40 | 2021-2025 | Siliq, Duobrii, Jublia |
| Galderma Laboratories, L.P. | $412.06 | 2021-2025 | Nemluvio, Aklief |
| Organogenesis INC. | $244.63 | 2024-2025 | Puraply Wound Matrix, Puraforce, Via Matrix |
| Epi Health, LLC | $223.11 | 2021-2022 | |
| Organon LLC | $198.81 | 2023-2025 | Vtama, Hadlima |
| Janssen Scientific Affairs, LLC | $118.24 | 2022-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.81 | 2023-2025 | Spevigo, Cyltezo |
| Genentech USA, INC. | $73.46 | 2021-2022 | |
| Almirall LLC | $67.61 | 2021-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $61.57 | 2021 | |
| Mayne Pharma Commercial LLC | $43.43 | 2022-2023 | |
| Journey Medical Corporation | $34.35 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $24.92 | 2024 | |
| Biofrontera INC. | $19.33 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Cranial Technologies, INC | $17.30 | 2024 | Doc Band |
| Botanix Sb INC | $16.98 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $16.49 | 2025 | Ycanth |
| Cipher Pharmaceuticals US LLC | $14.27 | 2025 | Spinosad, Natroba |
| Biowound Solutions, INC. | $11.28 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.